CHI-921 / Canopy Growth - LARVOL DELTA

Investigation of the Efficacy and Safety of CHI-921 in Insomnia. (clinicaltrials.gov) - P2; N=21; Terminated; Sponsor: Canopy Growth Corporation; N=110 ➔ 21; Trial completion date: Sep 2020 ➔ Jun 2020; Recruiting ➔ Terminated; Trial primary completion date: Sep 2020 ➔ Jun 2020; COVID-19

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial termination • CNS Disorders • Insomnia • Sleep Disorder